Marking a strategic shift in healthcare innovation in the Middle East, Burjeel Holdings and U.S.-based nonprofit Caring Cross have announced plans to establish a Good Manufacturing Practice (GMP) facility in Abu Dhabi dedicated to the local, cost-effective production of chimeric antigen receptor T-cell (CAR-T) therapies. This partnership aims to address the dual challenge of affordability and accessibility for advanced therapies in the region—a space rapidly emerging as a global player in biomanufacturing innovation (Abbott, 2025).

CAR-T therapies represent one of the most promising advancements in modern oncology, offering personalized, immune-based treatments that reengineer a patient’s own T-cells to recognize and destroy cancer cells. These therapies have shown dramatic results in certain blood cancers, but their availability has been limited by high costs, complex logistics, and centralized manufacturing models.

According to Burjeel’s Director of Hematology Oncology & Cellular Therapy, Ajlan Al Zaki, the new facility will be capable of simultaneously processing up to 200 samples, enabling point-of-care manufacturing of cell therapies in proximity to patients. This decentralized approach represents a significant departure from traditional centralized models, which often involve costly, logistically complex pipelines and long turnaround times.

Boro Dropulić, CEO of Caring Cross, emphasized that the UAE’s investments in regulatory infrastructure and skilled workforce development have created a favorable environment for such pioneering efforts. “These steps align closely with the UAE’s long-term vision for healthcare innovation and regional resilience in medicine manufacturing,” Dropulić stated (Abbott, 2025).

From Pilot to Playbook: Lessons for Tomorrow’s Medicines Development Leader

This partnership is a clear reflection of emerging trends in pharmaceutical medicine that are highly relevant to learners in the GMDP Academy, particularly those focused on manufacturing innovation, regulatory adaptation, and health equity. Key programmatic ties include:

  • Module 3: Drug Discovery, Exploratory and Confirmatory Development, where learners study translational medicine models that reduce time-to-market and localize innovation.
  • Module 4: Clinical Trials: From Concept to Study Report, with its focus on ethical recruitment, patient consent processes, and safety monitoring—each exemplified in Burjeel’s patient-centric approach.
  • Module 5: Regulatory Affairs, Drug Safety and Pharmacovigilance, which underscores the need for regional regulatory harmonization and policy-driven innovation in manufacturing.
  • Module 8: Digital Technology in Medicines Development, where decentralized production models intersect with data management and tech-enabled process optimization.

As discussed in Silva et al. (2021), a competent global workforce must be agile in responding to local healthcare priorities while upholding the highest standards of safety, quality, and ethics. The UAE model—where patients are supported by navigators, informed through peer-led advocacy, and monitored through tailored outpatient protocols—offers a blueprint for patient-centric care in emerging markets.

Why This Matters

For the next generation of medicines development leaders, stories like this are more than headlines—they are case studies in global health innovation, policy alignment, and equity-driven strategy. As partnerships like Burjeel and Caring Cross forge new paths in cost-effective cell therapy delivery, GMDP learners are challenged to think beyond borders, beyond conventional models, and toward a future where access is engineered into every solution.

References

Abbott, J. (2025, April 15). Burjeel and Caring Cross team to optimize CAR-T production in UAE. BioProcess Insider. https://www.bioprocessintl.com/deal-making/burjeel-and-caring-cross-team-to-optimize-car-t-production-in-uae

Silva, H., Stonier, P. D., Kerpel-Fronius, S., & Dubois, D. J. (Eds.). (2021). Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers in Pharmacology. https://doi.org/10.3389/978-2-88966-986-8

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred